Bridging the Gap
Molecular diagnostics has the potential to improve the quality of healthcare by improving the accuracy, simplicity and accessibility to advanced diagnostic solutions, even in remote areas where skilled manpower and infrastructure is a challenge.
Molecular diagnostics has limited access in India. As a result, doctors are often forced to make judgment calls based on incomplete information or send the patient samples across / outside the country (costly and time consuming) for accurate diagnosis.
Rivaara focuses on Accessibility, Awareness and Affordability as key levers to transforming molecular diagnostics in India:
Affordability:
Distance between the place where the test is conducted and where it is sent for diagnosis due to limited PCR Labs leads to delay in reporting and makes these tests expensive. This has kept HCPs deprived from doing many “confirmatory” tests in infectious disease.
Accessibility:
For a population of over 1.3 billion, there are only around 400 PCR machines in the entire country. With growing disease burdens, access will be a key growth driver. This gives immense scope to innovate and commercialise PCR tests for India specific diseases.
Awareness:
Many doctors are unaware of the complete benefits of Molecular Diagnostics & POC technologies. Lack of education channels within the industry has further added to limited percolation of latest technologies and advancements amongst HCPs.
We ensure that Molecular Diagnostics on demand is accessible across India with a level of simplicity that allows easy adoption. Our network of molecular diagnostic labs ensures extensive test accessibility across – infectious diseases, oncology, gynecology, immunology, critical care and other therapy areas.
Management Team | Our Culture | Our Capabilities | Enabling Clinicians
